Biotech Market News
What Is Insider Buying and Selling in Biotech? Reading Form 4 Filings
When a biotech company’s CEO or Chief Medical Officer buys a significant amount of company stock with their own money, it can be a meaningful signal — insiders generally have access to more detailed, real-time information about the company’s clinical and regulatory trajectory than any outside investor. But insider transaction data is nuanced, frequently misinterpreted,…
Theralase Closes C$3.6M Financing for Ruvidar Development
Theralase Technologies Inc. (TSXV: TLT; OTCQB: TLTFF) has closed a brokered private placement that raised gross proceeds of C$3.555 million, providing additional capital for its cancer and antiviral development programs. According to the August 24 announcement, Theralase issued 14,812,500 units at C$0.24 per unit. Each unit contains one common share and one warrant exercisable at…
Amplitude Therapeutics Partners With Lilly on taRNA Vaccines
Amplitude Therapeutics, a private Boston-based biotechnology company, announced on August 19 a strategic research collaboration and licensing agreement with Eli Lilly and Company (NYSE: LLY) to discover and develop vaccines using Amplitude’s trans-amplifying RNA (taRNA) platform for infectious diseases. The companies did not name the specific diseases involved, describing the initial focus only as infectious…
Inside Piramal’s $7.95M Buyout of Biologics CDMO Yapan Bio
Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) announced on August 18 that it has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based contract development and manufacturing organization (CDMO) specializing in vaccines and biologics, for aggregate cash consideration of 76 crore rupees, or roughly $7.95 million. The purchase brings…
What Drives Biotech M&A? Understanding Why Big Pharma Acquires Small Biotechs
Biotech M&A headlines are among the most consistently exciting news events in the sector — a large pharmaceutical company announces an acquisition of a smaller biotech, often at a premium of 50%, 80%, or well over 100% above the target’s prior trading price. Understanding what drives these acquisitions, how they are structured, and how to…
Qiming Leads $12M Round for Heart Pump Maker Enginprime
Enginprime Medical, a Shanghai and Hangzhou-based developer of percutaneous ventricular assist device (pVAD) technology, announced on August 17 that it has closed a $12 million Series A financing round exclusively led by Qiming Venture Partners, a large, established venture capital firm. Proceeds will fund a registration clinical trial of Enginprime’s lead device, OpusOne, in China,…
Actinium Discloses NYSE Listing Deficiency, Patent Gains
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced on August 14 a mix of intellectual property and manufacturing progress for its lead radiotherapy candidate Actimab-A, alongside a separate and more consequential disclosure: NYSE Regulation has accepted the company’s plan to regain compliance with the exchange’s continued listing standards, after confirming Actinium is not currently meeting two…
Inside Atrium Therapeutics’ Q2 2026 Earnings and New Trial
Atrium Therapeutics, Inc. (Nasdaq: RNA) reported second-quarter 2026 financial results on August 13, disclosing that the FDA has cleared its Investigational New Drug (IND) application for ATR 1072, its first precision cardiology program to enter human testing, alongside a second $15 million milestone payment earned under its cardiovascular collaboration with Bristol Myers Squibb. The San…
What Is Institutional Ownership in Biotech? Why It Matters for Retail Investors
When a well-known healthcare-focused hedge fund or a specialized biotech mutual fund takes a significant position in a clinical-stage company, retail investors often take notice — and for good reason. Institutional investors in biotech frequently employ dedicated scientific and clinical staff, including MDs and PhDs, to conduct deep diligence on clinical trial design, competitive landscape,…
Daiichi Sankyo Taps Innovent to Sell Vanflyta in China
Innovent Biologics, Inc. (HKEX: 01801) and Daiichi Sankyo Company (TSE: 4568) announced on August 9 that they have entered an exclusive agreement to commercialize Vanflyta (quizartinib) in China, an oral FLT3 inhibitor for a genetically defined, high-risk form of acute myeloid leukemia. Under the deal, Daiichi Sankyo keeps responsibility for developing, manufacturing, and supplying the…
